metricas
covid
Buscar en
Medicina Clínica
Toda la web
Inicio Medicina Clínica Evolución del impacto socioeconómico de las biotecnologías
Journal Information
Vol. 131. Issue S5.
Pages 48-54 (December 2009)
Share
Share
Download PDF
More article options
Vol. 131. Issue S5.
Pages 48-54 (December 2009)
Evolución del impacto socioeconómico de las biotecnologías
Evolution of the socio-economic impact of health-related
Visits
112031
Emilio Muñoza
a Centro de Ciencias Humanas y Sociales. Instituto de Filosofía. CSIC. Madrid. España.
This item has received
Article information
La valoración del impacto socioeconómico de las biotecnologías surge como necesidad de su carácter estratégico para todos los sectores de la economía, y de modo particular en el de la salud. Sin embargo, este objetivo presenta muchas dificultades por el carácter transversal y multifacético de las tecnologías de la vida, lo que dificulta los tratamientos estadísticos. Los esfuerzos de organismos internacionales como la OCDE y la Comisión Europea y Eurostat han permitido abordar el problema a base de realizar encuestas a los actores implicados, tomados en un sentido amplio.
En el caso español, los esfuerzos de instituciones públicas y privadas, como la Fundación Genoma España, la asociación empresarial ASEBIO y, más recientemente, el Instituto Nacional de Estadística, han permitido conseguir avances y estimar el notable papel innovador que ofrece el desarrollo del mundo empresarial en biotecnología orientada a la salud, complementando así la notable base científica de que se dispone en España en estos campos científico-técnicos.
Palabras clave:
Sector estratégico
Carácter transversal
Dificultades estadísticas
Organismos internacionales
Instituciones públicas y privadas
Empresas innovadoras
The socioeconomic impacts of biotechnology applications need to be assessed due to their strategic character for all economic sectors and, particularly, for the health sector. However, this objective is not without difficulties in view of the horizontal and multifaceted character of life technologies, which hampers statistical analysis. The initiatives of international organizations such as the Organization for Economic Cooperation and Development (OECD), the European Commission and Eurostat are helping to solve the problem and results are emerging from the use of questionnaires addressed to the actors (in the broad sense of the term) involved. In the case of Spain, the efforts of public and private institutions such as the Spanish Genome Foundation and the entrepreneurial association ASEBIO, together with the more recent intervention of the National Statistics Institute, have allowed considerable advances to be achieved and the important innovative character of health-oriented biotechnology to be recognized as a valid complement to the strong scientific and technical potential of the Spanish biotechnology community.
Keywords:
Strategic sector
Transversal technologies
Statistical limitations
International organizations
Public and private institutions
Innovative business development

Article

These are the options to access the full texts of the publication Medicina Clínica
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos